<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31859676</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2291-5222</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>12</Issue><PubDate><Year>2019</Year><Month>Dec</Month><Day>20</Day></PubDate></JournalIssue><Title>JMIR mHealth and uHealth</Title><ISOAbbreviation>JMIR Mhealth Uhealth</ISOAbbreviation></Journal><ArticleTitle>Objectively Monitoring Amyotrophic Lateral Sclerosis Patient Symptoms During Clinical Trials With Sensors: Observational Study.</ArticleTitle><Pagination><StartPage>e13433</StartPage><MedlinePgn>e13433</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e13433</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/13433</ELocationID><Abstract><AbstractText Label="BACKGROUND">Objective symptom monitoring of patients with Amyotrophic Lateral Sclerosis (ALS) has the potential to provide an important source of information to evaluate the impact of the disease on aspects of real-world functional capacity and activities of daily living in the home setting, providing useful objective outcome measures for clinical trials.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to investigate the feasibility of a novel digital platform for remote data collection of multiple symptoms-physical activity, heart rate variability (HRV), and digital speech characteristics-in 25 patients with ALS in an observational clinical trial setting to explore the impact of the devices on patients' everyday life and to record tolerability related to the devices and study procedures over 48 weeks.</AbstractText><AbstractText Label="METHODS">In this exploratory, noncontrolled, nondrug study, patients attended a clinical site visit every 3 months to perform activity reference tasks while wearing a sensor, to conduct digital speech tests and for conventional ALS monitoring. In addition, patients wore the sensor in their daily life for approximately 3 days every month for the duration of the study.</AbstractText><AbstractText Label="RESULTS">The amount and quality of digital speech data captured at the clinical sites were as intended, and there were no significant issues. All the home monitoring sensor data available were propagated through the system and were received as expected. However, the amount and quality of physical activity home monitoring data were lower than anticipated. A total of 3 or more days (or partial days) of data were recorded for 65% of protocol time points, with no data collected for 24% of time points. At baseline, 24 of 25 patients provided data, reduced to 13 of 18 patients at Week 48. Lower-than-expected quality HRV data were obtained, likely because of poor contact between the sensor and the skin. In total, 6 of 25 patients had mild or moderate adverse events (AEs) in the skin and subcutaneous tissue disorders category because of skin irritation caused by the electrode patch. There were no reports of serious AEs or deaths. Most patients found the sensor comfortable, with no or minimal impact on daily activities.</AbstractText><AbstractText Label="CONCLUSIONS">The platform can measure physical activity in patients with ALS in their home environment; patients used the equipment successfully, and it was generally well tolerated. The quantity of home monitoring physical activity data was lower than expected, although it was sufficient to allow investigation of novel physical activity end points. Good-quality in-clinic speech data were successfully captured for analysis. Future studies using objective patient monitoring approaches, combined with the most current technological advances, may be useful to elucidate novel digital biomarkers of disease progression.</AbstractText><CopyrightInformation>&#xa9;Luis Garcia-Gancedo, Madeline L Kelly, Arseniy Lavrov, Jim Parr, Rob Hart, Rachael Marsden, Martin R Turner, Kevin Talbot, Theresa Chiwera, Christopher E Shaw, Ammar Al-Chalabi. Originally published in JMIR mHealth and uHealth (http://mhealth.jmir.org), 20.12.2019.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garcia-Gancedo</LastName><ForeName>Luis</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-5631-1711</Identifier><AffiliationInfo><Affiliation>Advanced Biostatistics &amp; Data Analytics Centre of Excellence, R&amp;D Projects Clinical Platforms &amp; Sciences, GlaxoSmithKline, Stevenage, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>Madeline L</ForeName><Initials>ML</Initials><Identifier Source="ORCID">0000-0001-6855-4550</Identifier><AffiliationInfo><Affiliation>Translational Medicine, Future Pipeline Discovery, GlaxoSmithKline, Stevenage, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavrov</LastName><ForeName>Arseniy</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2360-2253</Identifier><AffiliationInfo><Affiliation>Clinical Development, AveXis, Bannockburn, IL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parr</LastName><ForeName>Jim</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5956-217X</Identifier><AffiliationInfo><Affiliation>McLaren Technology Centre, McLaren Applied Technologies, Woking, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hart</LastName><ForeName>Rob</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-8507-3326</Identifier><AffiliationInfo><Affiliation>McLaren Technology Centre, McLaren Applied Technologies, Woking, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marsden</LastName><ForeName>Rachael</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-0304-9427</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0267-3180</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talbot</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-5490-1697</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiwera</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-2884-4267</Identifier><AffiliationInfo><Affiliation>Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, King's College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials><Identifier Source="ORCID">0000-0003-0251-0146</Identifier><AffiliationInfo><Affiliation>Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, King's College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4924-7712</Identifier><AffiliationInfo><Affiliation>Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, King's College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ALCHALABI-TALBOT/APR14/926-794</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0500289</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_17115</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>TURNER/OCT18/989-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Mhealth Uhealth</MedlineTA><NlmUniqueID>101624439</NlmUniqueID><ISSNLinking>2291-5222</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="N">Exercise</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006339" MajorTopicYN="N">Heart Rate</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008991" MajorTopicYN="N">Monitoring, Physiologic</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013060" MajorTopicYN="N">Speech</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013672" MajorTopicYN="N">Technology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076251" MajorTopicYN="N">Wearable Electronic Devices</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">accelerometer</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">digital biomarker</Keyword><Keyword MajorTopicYN="N">digital phenotyping</Keyword><Keyword MajorTopicYN="N">heart rate</Keyword><Keyword MajorTopicYN="N">objective symptom monitoring</Keyword><Keyword MajorTopicYN="N">physical activity</Keyword><Keyword MajorTopicYN="N">speech</Keyword><Keyword MajorTopicYN="N">wearable</Keyword></KeywordList><CoiStatement>Conflicts of Interest: LG-G and MLK are employees of GSK and hold stocks/shares. At the time of the study, AL was an employee of GSK; currently, he holds stocks/shares. CES has previously consulted for GSK (&gt;5 years ago), has received research grants from Vertex and Chronos Therapeutics in the past, and has an active grant with Eli Lily. AA-C reports consultancies for GSK, Cytokinetics, Biogen Idec, Treeway Inc, Chronos Therapeutics, OrionPharma, and Mitsubishi-Tanabe Pharma and was chief investigator for commercial clinical trials run by OrionPharma and Cytokinetics. JP, RH, RM, MRT, KT, and TC have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31859676</ArticleId><ArticleId IdType="pmc">PMC6942190</ArticleId><ArticleId IdType="doi">10.2196/13433</ArticleId><ArticleId IdType="pii">v7i12e13433</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942&#x2013;55. doi: 10.1016/s0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot K. Motor neuron disease: the bare essentials. Pract Neurol. 2009 Oct;9(5):303&#x2013;9. doi: 10.1136/jnnp.2009.188151.9/5/303</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.188151</ArticleId><ArticleId IdType="pubmed">19762894</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994 Mar 3;330(9):585&#x2013;91. doi: 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Meurgey J, Jones A, Leigh PN, Bensimon G, Al-Chalabi A. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018;17(5):416&#x2013;22. doi: 10.1016/s1474-4422(18)30054-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(18)30054-1</ArticleId><ArticleId IdType="pmc">PMC5899963</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, van den Berg LH. Edaravone: a new treatment for ALS on the horizon? Lancet Neurol. 2017 Jul;16(7):490&#x2013;1. doi: 10.1016/S1474-4422(17)30163-1.S1474-4422(17)30163-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30163-1</ArticleId><ArticleId IdType="pubmed">28522180</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? Front Aging Neurosci. 2017;9:68. doi: 10.3389/fnagi.2017.00068. doi: 10.3389/fnagi.2017.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Katyal N, Govindarajan R. Shortcomings in the current amyotrophic lateral sclerosis trials and potential solutions for improvement. Front Neurol. 2017;8:521. doi: 10.3389/fneur.2017.00521. doi: 10.3389/fneur.2017.00521.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00521</ArticleId><ArticleId IdType="doi">10.3389/fneur.2017.00521</ArticleId><ArticleId IdType="pmc">PMC5626834</ArticleId><ArticleId IdType="pubmed">29033893</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J Neurol Sci. 1999 Oct 31;169(1-2):13&#x2013;21. doi: 10.1016/s0022-510x(99)00210-5.S0022510X99002105</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>ClinicalTrials.  [2018-11-08].  ALS Testing Through Home-based Outcome Measures (ALS AT HOME)  https://www.clinicaltrials.gov/ct2/show/NCT03016897
.</Citation></Reference><Reference><Citation>Prell T, Ringer T, Witte O, Grosskreutz J. Heart rate variability is decreased in patients with amyotrophic lateral sclerosis. Clin Neurophysiol. 2015;126(8):e117. doi: 10.1016/j.clinph.2015.04.180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2015.04.180</ArticleId></ArticleIdList></Reference><Reference><Citation>Yunusova Y, Green JR, Greenwood L, Wang J, Pattee GL, Zinman L. Tongue movements and their acoustic consequences in amyotrophic lateral sclerosis. Folia Phoniatr Logop. 2012;64(2):94&#x2013;102. doi: 10.1159/000336890. 
 
000336890</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000336890</ArticleId><ArticleId IdType="pmc">PMC3369262</ArticleId><ArticleId IdType="pubmed">22555651</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001;344(22):1688&#x2013;700. doi: 10.1056/nejm200105313442207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejm200105313442207</ArticleId><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293&#x2013;9. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology. 2002 Oct 8;59(7):1077&#x2013;9. doi: 10.1212/wnl.59.7.1077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.59.7.1077</ArticleId><ArticleId IdType="pubmed">12370467</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Jozsa F, Al-Chalabi A. Nonmotor symptoms in amyotrophic lateral sclerosis: a systematic review. Int Rev Neurobiol. 2017;134:1409&#x2013;41. doi: 10.1016/bs.irn.2017.04.009.S0074-7742(17)30039-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.irn.2017.04.009</ArticleId><ArticleId IdType="pubmed">28805578</ArticleId></ArticleIdList></Reference><Reference><Citation>Chida K, Sakamaki S, Takasu T. Alteration in autonomic function and cardiovascular regulation in amyotrophic lateral sclerosis. J Neurol. 1989 Mar;236(3):127&#x2013;30. doi: 10.1007/bf00314326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/bf00314326</ArticleId><ArticleId IdType="pubmed">2709061</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto T, Yoshiuchi K, Inada S, Shirakura K, Wada N, Takeuchi K, Matsushita M. Physical activity of elderly patients with rheumatoid arthritis and healthy individuals: an actigraphy study. Biopsychosoc Med. 2015;9:19. doi: 10.1186/s13030-015-0046-0. 
 
46</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13030-015-0046-0</ArticleId><ArticleId IdType="doi">10.1186/s13030-015-0046-0</ArticleId><ArticleId IdType="pmc">PMC4593190</ArticleId><ArticleId IdType="pubmed">26442128</ArticleId></ArticleIdList></Reference><Reference><Citation>van Buul AR, Kasteleyn MJ, Chavannes NH, Taube C. Physical activity in the morning and afternoon is lower in patients with chronic obstructive pulmonary disease with morning symptoms. Respir Res. 2018 Mar 27;19(1):49. doi: 10.1186/s12931-018-0749-4. 
 
10.1186/s12931-018-0749-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-018-0749-4</ArticleId><ArticleId IdType="doi">10.1186/s12931-018-0749-4</ArticleId><ArticleId IdType="pmc">PMC5870529</ArticleId><ArticleId IdType="pubmed">29587841</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsmeier F, Taylor KI, Kilchenmann T, Wolf D, Scotland A, Schjodt-Eriksen J, Cheng W, Fernandez-Garcia I, Siebourg-Polster J, Jin L, Soto J, Verselis L, Boess F, Koller M, Grundman M, Monsch AU, Postuma RB, Ghosh A, Kremer T, Czech C, Gossens C, Lindemann M. Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial. Mov Disord. 2018 Aug;33(8):1287&#x2013;97. doi: 10.1002/mds.27376. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27376</ArticleId><ArticleId IdType="pmc">PMC6175318</ArticleId><ArticleId IdType="pubmed">29701258</ArticleId></ArticleIdList></Reference><Reference><Citation>Linden D, Diehl RR, Berlit P. Reduced baroreflex sensitivity and cardiorespiratory transfer in amyotrophic lateral sclerosis. Electroencephalogr Clin Neurophysiol. 1998 Oct;109(5):387&#x2013;90. doi: 10.1016/s0924-980x(98)00035-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0924-980x(98)00035-6</ArticleId><ArticleId IdType="pubmed">9851294</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, Pinto A, De Carvalho M. Decreased heart rate variability predicts death in amyotrophic lateral sclerosis. Muscle Nerve. 2012 Sep;46(3):341&#x2013;5. doi: 10.1002/mus.23313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.23313</ArticleId><ArticleId IdType="pubmed">22907223</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundy DS, Roy S, Xue JW, Casiano RR, Jassir D. Spastic/spasmodic vs tremulous vocal quality: motor speech profile analysis. J Voice. 2004 Mar;18(1):146&#x2013;52. doi: 10.1016/j.jvoice.2003.12.001.S089219970300170X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvoice.2003.12.001</ArticleId><ArticleId IdType="pubmed">15070235</ArticleId></ArticleIdList></Reference><Reference><Citation>Rong P, Yunusova Y, Wang J, Zinman L, Pattee GL, Berry JD, Perry B, Green JR. Predicting speech intelligibility decline in amyotrophic lateral sclerosis based on the deterioration of individual speech subsystems. PLoS One. 2016;11(5):e0154971. doi: 10.1371/journal.pone.0154971. 
 
PONE-D-15-42524</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0154971</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0154971</ArticleId><ArticleId IdType="pmc">PMC4858181</ArticleId><ArticleId IdType="pubmed">27148967</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis RJ, Zhu B, Koenig J, Thayer JF, Wang Y. A careful look at ECG sampling frequency and R-peak interpolation on short-term measures of heart rate variability. Physiol Meas. 2015 Sep;36(9):1827&#x2013;52. doi: 10.1088/0967-3334/36/9/1827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/0967-3334/36/9/1827</ArticleId><ArticleId IdType="pubmed">26234196</ArticleId></ArticleIdList></Reference><Reference><Citation>Task Force of the European Society of Cardiology and the North American Society of Pacing Electrophysiology Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation. 1996 Mar 1;93(5):1043&#x2013;65. doi: 10.1161/01.cir.93.5.1043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.cir.93.5.1043</ArticleId><ArticleId IdType="pubmed">8598068</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreu-Perez J, Garcia-Gancedo L, McKinnell J, van der Drift A, Powell A, Hamy V, Keller T, Yang G. Developing fine-grained actigraphies for rheumatoid arthritis patients from a single accelerometer using machine learning. Sensors (Basel) 2017 Sep 14;17(9):pii: E2113. doi: 10.3390/s17092113. 
 
s17092113</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/s17092113</ArticleId><ArticleId IdType="pmc">PMC5620953</ArticleId><ArticleId IdType="pubmed">28906437</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Trials Transformation Initiative. Durham, North Carolina: 2017. Jun,  [2018-11-08].  Developing Novel Endpoints Generated by Mobile Technology for Use in Clinical Trials  https://www.ctti-clinicaltrials.org/briefing-room/recommendations/developing-novel-endpoints-generated-mobile-technology-use-clinical
.</Citation></Reference><Reference><Citation>Kuss O, Schumann B, Kluttig A, Greiser KH, Haerting J. Time domain parameters can be estimated with less statistical error than frequency domain parameters in the analysis of heart rate variability. J Electrocardiol. 2008;41(4):287&#x2013;91. doi: 10.1016/j.jelectrocard.2008.02.014.S0022-0736(08)00062-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jelectrocard.2008.02.014</ArticleId><ArticleId IdType="pubmed">18367200</ArticleId></ArticleIdList></Reference><Reference><Citation>Yunusova Y, Graham NL, Shellikeri S, Phuong K, Kulkarni M, Rochon E, Tang-Wai DF, Chow TW, Black SE, Zinman LH, Green JR. Profiling Speech and Pausing in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) PLoS One. 2016;11(1):e0147573. doi: 10.1371/journal.pone.0147573. 
 
PONE-D-15-43989</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0147573</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0147573</ArticleId><ArticleId IdType="pmc">PMC4720472</ArticleId><ArticleId IdType="pubmed">26789001</ArticleId></ArticleIdList></Reference><Reference><Citation>WebCite.  [2019-11-27].  Explore 289,090 Research Studies in All 50 States and in 205 Countries  https://www.webcitation.org/73m1rJyNU
.</Citation></Reference><Reference><Citation>DasMahapatra P, Chiauzzi E, Bhalerao R, Rhodes J. Free-living physical activity monitoring in adult US patients with multiple sclerosis using a consumer wearable device. Digit Biomark. 2018;2(1):47&#x2013;63. doi: 10.1159/000488040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000488040</ArticleId><ArticleId IdType="pmc">PMC7015360</ArticleId><ArticleId IdType="pubmed">32095756</ArticleId></ArticleIdList></Reference><Reference><Citation>Crouthamel M, Quattrocchi E, Watts S, Wang S, Berry P, Garcia-Gancedo L, Hamy V, Williams RE. Using a ResearchKit Smartphone App to Collect Rheumatoid Arthritis Symptoms From Real-World Participants: Feasibility Study. JMIR Mhealth Uhealth. 2018 Sep 13;6(9):e177. doi: 10.2196/mhealth.9656. 
 
v6i9e177</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/mhealth.9656</ArticleId><ArticleId IdType="pmc">PMC6231853</ArticleId><ArticleId IdType="pubmed">30213779</ArticleId></ArticleIdList></Reference><Reference><Citation>Gimeno-Santos E, Raste Y, Demeyer H, Louvaris Z, de Jong C, Rabinovich RA, Hopkinson NS, Polkey MI, Vogiatzis I, Tabberer M, Dobbels F, Ivanoff N, de Boer WI, van der Molen T, Kulich K, Serra I, Basaga&#xf1;a X, Troosters T, Puhan MA, Karlsson N, Garcia-Aymerich J, PROactive consortium  The PROactive instruments to measure physical activity in patients with chronic obstructive pulmonary disease. Eur Respir J. 2015 Oct;46(4):988&#x2013;1000. doi: 10.1183/09031936.00183014. 
 
09031936.00183014</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00183014</ArticleId><ArticleId IdType="pmc">PMC4589432</ArticleId><ArticleId IdType="pubmed">26022965</ArticleId></ArticleIdList></Reference><Reference><Citation>Andres PL, Skerry LM, Munsat TL, Thornell BJ, Szymonifka J, Schoenfeld DA, Cudkowicz ME. Validation of a new strength measurement device for amyotrophic lateral sclerosis clinical trials. Muscle Nerve. 2012 Jan;45(1):81&#x2013;5. doi: 10.1002/mus.22253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.22253</ArticleId><ArticleId IdType="pubmed">22190312</ArticleId></ArticleIdList></Reference><Reference><Citation>Doherty A, Jackson D, Hammerla N, Pl&#xf6;tz T, Olivier P, Granat MH, White T, van Hees VT, Trenell MI, Owen CG, Preece SJ, Gillions R, Sheard S, Peakman T, Brage S, Wareham NJ. Large scale population assessment of physical activity using wrist worn accelerometers: The UK Biobank study. PLoS One. 2017;12(2):e0169649. doi: 10.1371/journal.pone.0169649. 
 
PONE-D-16-26249</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0169649</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0169649</ArticleId><ArticleId IdType="pmc">PMC5287488</ArticleId><ArticleId IdType="pubmed">28146576</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourdillon N, Schmitt L, Yazdani S, Vesin JM, Millet GP. Minimal window duration for accurate HRV recording in athletes. Front Neurosci. 2017;11:456. doi: 10.3389/fnins.2017.00456. doi: 10.3389/fnins.2017.00456.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2017.00456</ArticleId><ArticleId IdType="doi">10.3389/fnins.2017.00456</ArticleId><ArticleId IdType="pmc">PMC5554345</ArticleId><ArticleId IdType="pubmed">28848382</ArticleId></ArticleIdList></Reference><Reference><Citation>Bot BM, Suver C, Neto EC, Kellen M, Klein A, Bare C, Doerr M, Pratap A, Wilbanks J, Dorsey ER, Friend SH, Trister AD. The mPower study, Parkinson disease mobile data collected using ResearchKit. Sci Data. 2016 Mar 3;3:160011. doi: 10.1038/sdata.2016.11. 
 
sdata201611</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2016.11</ArticleId><ArticleId IdType="pmc">PMC4776701</ArticleId><ArticleId IdType="pubmed">26938265</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>